Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
BioSpace18h
Vertex Severs Liver Gene Therapies Partnership with Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
BioPharma Dive21h
Vertex ends gene editing research pact with Verve
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
ENDPOINTS NEWS22h
Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back as Ver­tex walks away from pact
Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...